The World's First $1 Trillion Drug

Dear Reader,   It’s being called “a miracle.”  And the “holy grail of medicine.” That’s “widely expected to be one of the top-selling medicines in history.” They’re talking about new drugs called “GLP-1 agonists.” And everybody’s raving about them because they make weight loss easy.  No diet and no exercise required. It’s a dream come true for dieters. Which is why some Wall Street analysts are predicting these drugs will generate $200 billion annually by 2030.  That’s more revenue than the current top-10 selling medicines generate… combined. But former hedge fund manager Ian King says Wall Street is WRONG. Because of one line he found in this official FDA document, he says Wall Street is vastly UNDERESTIMATING the potential.  Instead… Ian predicts this could become the world’s first trillion-dollar drug. And he’s recommending 3 little-known stocks to play this fast-moving trend.    Click here for all the details.        Regards,     Sarah Williams Associate Editorial Manager, Banyan Hill Publishing   P.S. This is a time-sensitive opportunity. Because of what Ian found in this FDA document, he believes the FDA could make a major announcement about GLP-1 drugs within the next 6 months. If that happens, he says the share prices of the 3 little-known stocks he’s recommending could skyrocket.      This ad is sent on behalf of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482.  If you would like to unsubscribe from receiving offers for Strategic Fortunes, please click here .

Stockguru LLC (dba InvestingChatter) 711 SW 24th Ave Boynton, Beach, FL 33435  This email is being sent from InvestingChatter. If you no longer wish to receive InvestingChatter emails, please  click to unsubscribe.

DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.